John Slack PhD - Project Management (Consultant)

John Slack provides project management consultancy services to Pharminox in relation to all aspects of development. He is a founding director of PharMomentum Ltd, and is a highly experienced biopharmaceutical company executive with over fifteen years in senior corporate and development roles. From 1996 to 2005 he was VP International Development for OSI Pharmaceuticals Inc, where he had overall responsibility for the international project management of the development programme for Tarceva, an EGFR inhibitor which is now approved for the treatment of lung cancer. He was also General Manager of OSI's UK subsidiary. Prior to that he was Managing Director of Aston Molecules Ltd, a contract research and development company that John spun out of Aston University and subsequently sold to OSI.

In his earlier career John spent 16 years in academic research, primarily in the field of cancer, including 10 years as a member of the Cancer Research Campaign Experimental Chemotherapy Group based at Aston University. He graduated in pharmacy in 1973 and has a PhD in analytical chemistry.

Marc G Hummersone PhD - Head of Chemistry

Marc joined Pharminox in April 2008 to work with Malcolm Stevens and the team on the initiation and progression of in-house drug discovery projects. Prior to joining Pharminox, Marc spent 6 years working with KuDOS Pharmaceuticals as a Medicinal Chemist, Group Leader and member of the Drug Research Management Team.

Marc graduated from Leeds University with a degree in Chemistry and subsequently pursued a PhD at University College London, under the supervision of Prof Karl J Hale, where he worked on the total synthesis of complex natural products. Post Doctoral research saw the completion of the formal synthesis of Bryostatin, a complex marine macrolide. Marc has authored and co-authored numerous publications in the field of oncology, chemistry and medicinal chemistry and is named as inventor on many patents.

Andrew Westwell PhD - Chemistry (Consultant)

Andy is currently a Senior Lecturer in Medicinal Chemistry at Cardiff University, having previously spent nine years in a senior role within the Nottingham cancer drug discovery and development group led by Malcolm Stevens. He has been intimately involved in the development of the antitumour benzothiazole and quinol programmes, and has been author/co-author for numerous publications in the field, as well as an inventor on the corresponding patent applications.

Andy graduated in Chemistry from the University of Leeds in 1990, and stayed in Leeds to complete his PhD in synthetic organic chemistry in 1994. He then spent two years as a postdoctoral research associate at Loughborough University before moving to the University of Nottingham in 1996 as a Senior Research Fellow with Malcolm Stevens. Andy was appointed to a Cancer Research UK Lectureship within the Nottingham School of Pharmacy in 2001, and a Senior Lectureship at Cardiff University in January 2006. In addition to his research and teaching activities, Andy is a regular correspondent for Drug Discovery Today in the area of novel antitumour molecules.

Tracey Bradshaw PhD Pharmacology (Consultant)

Tracey has over ten years experience as a senior pharmacologist in the Experimental Cancer Chemotherapy Group based in the School of Pharmacy at the University of Nottingham. She has played a key role in the investigation and elaboration of the mechanism of action and antitumour activity of a variety of novel experimental compounds originating within this Group including aminophenylbenzothiazoles, dimethoxyphenylbenzothiazoles and heterocyclic quinols. She has published extensively in these areas.

Tracey qualified in Anatomical Studies from the University of Birmingham in 1986 and received a PhD from the University of Aston in 1990. Prior to her current appopintment, Tracey held research posts in the Department of Medical Oncology, Charing Cross Hospital London, the Department of Pharmaceutical Sciences at the University of Aston and the Department of Pharmaceutical Sciences at the University of Nottingham.

Tracey is the recipient of numerous awards for her research to date and is also a member of the Drug Discovery Committee of European Organisation for the Research and Treatment of Cancer.